Insider · CIK 0001835184
Anthony D'Adamio
Files at BVS (Bioventus Inc.). First filing Dec 26, 2024, latest Apr 15, 2025.
In brief
Anthony D'Adamio files SEC Form 4 as officer at BVS (Bioventus Inc.). Since Dec 26, 2024, Anthony D'Adamio has reported 0 open-market buys worth $0 and 4 open-market sells worth $154k, the latest filed on Apr 15, 2025.
A track record needs three past buys with six months of prices behind them; Anthony D'Adamio has 0, so none is measured yet.
The newest scored trade: sold $22k of BVS on Apr 11, 2025, filed Apr 15, 2025, scored 10 (weak), under a 10b5-1 plan.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
BVS: Bioventus Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 10Weak | Bioventus Inc. | $22k 2,958 shares | -2% | 0% from low-45% from high | |
| 15Weak | Bioventus Inc. | $25k 2,615 shares | -2% | - | |
| 16Weak | Bioventus Inc. | $45k 4,380 shares | -4% | - | |
| 17Weak | Bioventus Inc. | $62k 5,848 shares | -5% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Apr 11, 2025 | BVS Bioventus Inc. | 4,000 0.01% of outstanding | $38k | Apr 11, 2025 | $70k |
| Dec 23, 2024 | BVS Bioventus Inc. | 16,000 0.02% of outstanding | $178k | Dec 23, 2024 | none |
Transactions
Every row this insider has filed, 28 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 10, 2026 | BVS Bioventus Inc. | MOption exercise Class A Common Stock | +9,925 | $0.00 | $0 | 157,967 | Apr 14, 2026 |
| Apr 10, 2026 | BVS Bioventus Inc. | FTax withholding Class A Common Stock | -4,312 | $9.06 | $39k | 153,655 | Apr 14, 2026 |
| Apr 10, 2026 | BVS Bioventus Inc. | MOption exercise Restricted Stock Unitsderivative | -9,925 | $0.00 | $0 | 9,925 | Apr 14, 2026 |
| Mar 13, 2026 | BVS Bioventus Inc. | MOption exercise Class A Common Stock | +8,886 | $0.00 | $0 | 146,955 | Mar 17, 2026 |
| Mar 13, 2026 | BVS Bioventus Inc. | FTax withholding Class A Common Stock | -3,861 | $8.62 | $33k | 143,094 | Mar 17, 2026 |
| Mar 13, 2026 | BVS Bioventus Inc. | MOption exercise Class A Common Stock | +8,750 | $0.00 | $0 | 151,844 | Mar 17, 2026 |
| Mar 13, 2026 | BVS Bioventus Inc. | FTax withholding Class A Common Stock | -3,802 | $8.62 | $33k | 148,042 | Mar 17, 2026 |
| Mar 14, 2025 | BVS Bioventus Inc. | AGrant or award Restricted Stock Unitsderivative | +35,000 | $0.00 | $0 | 35,000 | Mar 17, 2026 |
| Mar 14, 2025 | BVS Bioventus Inc. | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Mar 17, 2026 |
| Mar 13, 2026 | BVS Bioventus Inc. | AGrant or award Restricted Stock Unitsderivative | +83,000 | $0.00 | $0 | 83,000 | Mar 17, 2026 |
| Mar 13, 2026 | BVS Bioventus Inc. | AGrant or award Stock Option (Right to Buy)derivative | +92,000 | $0.00 | $0 | 92,000 | Mar 17, 2026 |
| Mar 13, 2026 | BVS Bioventus Inc. | MOption exercise Restricted Stock Unitsderivative | -8,886 | $0.00 | $0 | 0 | Mar 17, 2026 |
| Mar 13, 2026 | BVS Bioventus Inc. | MOption exercise Restricted Stock Unitsderivative | -8,750 | $0.00 | $0 | 26,250 | Mar 17, 2026 |
| Feb 15, 2026 | BVS Bioventus Inc. | MOption exercise Class A Common Stock | +12,980 | $0.00 | $0 | 144,396 | Feb 18, 2026 |
| Feb 15, 2026 | BVS Bioventus Inc. | FTax withholding Class A Common Stock | -6,327 | $8.27 | $52k | 138,069 | Feb 18, 2026 |
| Feb 15, 2026 | BVS Bioventus Inc. | MOption exercise Restricted Stock Unitsderivative | -12,980 | $0.00 | $0 | 25,960 | Feb 18, 2026 |
| Apr 11, 2025 | BVS Bioventus Inc. | SOpen-market sale Class A Common Stock10b5-1 | -2,958 | $7.57 | $22k | 131,416 | Apr 15, 2025 |
| Apr 10, 2025 | BVS Bioventus Inc. | MOption exercise Class A Common Stock | +9,925 | $0.00 | $0 | 134,374 | Apr 11, 2025 |
| Apr 10, 2025 | BVS Bioventus Inc. | MOption exercise Restricted Stock Unitsderivative | -9,925 | $0.00 | $0 | 19,850 | Apr 11, 2025 |
| Mar 17, 2025 | BVS Bioventus Inc. | SOpen-market sale Class A Common Stock10b5-1 | -2,615 | $9.75 | $25k | 124,449 | Mar 18, 2025 |
| Mar 14, 2025 | BVS Bioventus Inc. | MOption exercise Class A Common Stock | +8,886 | $0.00 | $0 | 127,064 | Mar 14, 2025 |
| Mar 14, 2025 | BVS Bioventus Inc. | MOption exercise Restricted Stock Unitsderivative | -8,886 | $0.00 | $0 | 8,886 | Mar 14, 2025 |
| Feb 18, 2025 | BVS Bioventus Inc. | SOpen-market sale Class A Common Stock10b5-1 | -4,380 | $10.19 | $45k | 118,178 | Feb 20, 2025 |
| Feb 15, 2025 | BVS Bioventus Inc. | MOption exercise Class A Common Stock | +12,980 | $0.00 | $0 | 122,558 | Feb 18, 2025 |
| Feb 15, 2025 | BVS Bioventus Inc. | MOption exercise Restricted Stock Unitsderivative | -12,980 | $0.00 | $0 | 38,940 | Feb 18, 2025 |
| Dec 23, 2024 | BVS Bioventus Inc. | SOpen-market sale Class A Common Stock10b5-1 | -5,848 | $10.53 | $62k | 109,578 | Dec 26, 2024 |
| Dec 20, 2024 | BVS Bioventus Inc. | MOption exercise Class A Common Stock | +19,850 | $0.00 | $0 | 115,426 | Dec 23, 2024 |
| Dec 20, 2024 | BVS Bioventus Inc. | MOption exercise Restricted Stock Unitsderivative | -19,850 | $0.00 | $0 | 0 | Dec 23, 2024 |
Questions about Anthony D'Adamio
Answered from the filings on this page, as of the latest one.
Is Anthony D'Adamio buying or selling?
Not in the last 12 months. Anthony D'Adamio's latest open-market trade on SEC Form 4 was sold $22k of BVS on Apr 11, 2025.
How did Anthony D'Adamio's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Anthony D'Adamio has 0.
Where does Anthony D'Adamio file Form 4?
Anthony D'Adamio has filed Form 4 at BVS (Bioventus Inc.) as SVP & General Counsel. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.